Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.

Benzinga · Sep 24, 2025

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

Benzinga · Sep 24, 2025

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK · Sep 24, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Spot gold trading just below Monday’s fresh record high

The Guardian - UK · Sep 24, 2025

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

Benzinga · Sep 22, 2025

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market

Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Benzinga · Sep 22, 2025

Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) rose sharply in pre-market trading after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism on Sep. 22.

Benzinga · Sep 22, 2025

Read news from The Economist, FT, and more,
with one subscription

Novartis Chief Eyes Ways To End Higher US Drug Prices: Media

Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans to pay less for their medicines, its chief said in an interview published Saturday.

International Business Times · Sep 20, 2025

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Inc (NYSE:OSCR) just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims Hers Health Inc (NYSE:HIMS) style moonshot comparisons — and short sellers may be sitting on a powder…

Benzinga · Sep 19, 2025

NHS drug pricing is all about the art of the deal

Letter: Better negotiation with big pharma could ease the process, writes Andrew Dillon, in response to an article by Polly Toynbee about Donald Trump’s complaints about NHS pricing

The Guardian - UK · Sep 18, 2025

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Guardian - UK · Sep 18, 2025

Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Shares of Bullish (NYSE:BLSH) rose sharply in pre-market trading after the company posted a profit for the second quarter after Wednesday's closing bell.

Benzinga · Sep 18, 2025

Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership

Co-Diagnostics Inc. (NASDAQ:CODX) shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data.

Benzinga · Sep 17, 2025

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK · Sep 16, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard · Sep 16, 2025

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

Benzinga · Sep 16, 2025

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing

Eli Lilly and Co. (NYSE:LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County.

The Guardian - UK · Sep 16, 2025

Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain

The NHS needs cheap drugs, and our economy needs a thriving pharma industry. The president threatens both – no wonder Labour is grovelling to him, says Guardian columnist Polly Toynbee

The Guardian - UK · Sep 16, 2025

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · Sep 15, 2025

Pharmacy leaders issue warning over ‘dangerous’ medicine delays

One pharmacist reported their patients waiting more than a week for a medication for bipolar and schizophrenia

The Guardian - UK · Sep 15, 2025

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

Benzinga · Sep 15, 2025

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga · Sep 15, 2025

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

Biotech firm aTyr Pharma Inc. (NASDAQ:ATYR) plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.

Benzinga · Sep 12, 2025

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Benzinga · Sep 12, 2025

Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case

A federal appeals court has upheld a $183.7 million judgment against Eli Lilly and Co. (NYSE:LLY), rejecting the drugmaker's attempt to overturn a whistleblower lawsuit that accused it of defrauding Medicaid.

The Independent UK · Sep 12, 2025

Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site

The investment had been set to create 1,000 jobs

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.